Vutrisiran - Alnylam Pharmaceuticals
Alternative Names: ALN-65492; ALN-TTRsc02; AMVUTTRALatest Information Update: 27 Jun 2024
At a glance
- Originator Alnylam Pharmaceuticals
- Class Amides; Amino sugars; Drug conjugates; Pyrrolidines; Small interfering RNA
- Mechanism of Action Prealbumin expression inhibitors; RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Transthyretin-related hereditary amyloidosis
Most Recent Events
- 24 Jun 2024 Efficacy and adverse events data from the phase III HELIOS-B trial in Transthyretin-related hereditary amyloidosis released by Alnylam Pharmaceuticals
- 18 Jun 2024 Registered for Transthyretin-related hereditary amyloidosis in Australia (SC)
- 30 Apr 2024 Alnylam Pharmaceuticals expands its agreement with Medison Pharma to commercialise vutrisiran in additional Latin America and APAC markets including Australia